KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Divestments: 2020-2024

Historic Divestments for Royalty Pharma (RPRX) over the last 4 years, with Dec 2024 value amounting to $23.6 million.

  • Royalty Pharma's Divestments fell 92.12% to $905,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $103.4 million, marking a year-over-year increase of 312.70%. This contributed to the annual value of $23.6 million for FY2024, which is 46.13% down from last year.
  • Per Royalty Pharma's latest filing, its Divestments stood at $23.6 million for FY2024, which was down 46.13% from $43.9 million recorded in FY2023.
  • Royalty Pharma's Divestments' 5-year high stood at $43.9 million during FY2023, with a 5-year trough of $523,000 in FY2021.
  • For the 2-year period, Royalty Pharma's Divestments averaged around $33.8 million, with its median value being $33.8 million (2023).
  • Data for Royalty Pharma's Divestments shows a maximum YoY tumbled of 96.53% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Royalty Pharma's Divestments stood at $15.1 million in 2020, then slumped by 96.53% to $523,000 in 2021, then reached $43.9 million in 2023, then crashed by 46.13% to $23.6 million in 2024.